Panicked Healthcare Lobbyists Descend On Massachusetts To Save The 60th Democratic Vote For Reform

MassMapby Joe Weisenthal
Business Insider
January 9, 2010

We’ve been following the special election in Massachusetts, where the GOP hopes to pull a surprise upset in the race to fill Ted Kennedy’s seat.

If they do pull it off, healthcare reform is instantly in trouble, as the Democrats drop below 60.

But money is coming to the rescue of Democrat Martha Coakley — healthcare industry lobbyist money, specifically.

Tim Carney identifies several of her top fundraisers. Take a look at who they represent:

Thomas Boggs, Patton Boggs: Bristol-Myers Squibb
Chuck Brain, Capitol Hill Strategies: Amgen, BIO, Merck, PhRMA
Susan Brophy, Glover Park Group: Blue Cross, Pfizer
Steven Champlin, Duberstein Group: AHIP, Novartis, Sanofi-Aventis
Licy Do Canto, Raben Group: Amgen
Gerald Cassidy, Cassidy & Associates: U. Mass Memorial Health Care
David Castagnetti, Mehlman, Vogel, Castagnetti: Abbot Labs, AHIP, Astra-Zenaca, General Electric, Humana, Merck, PhRMA.
Steven Elmendorf, Elmendorf Strategies: Medicines Company, PhRMA, United Health
Shannon Finley, Capitol Counsel: Amgen, Astra-Zeneca, Blue Cross, GE, PhRMA, Sanofi-Aventis.
Heather Podesta, Heather Podesta & Partners: Cigna, Eli Lilly, HealthSouth
Tony Podesta, Podesta Group: Amgen, GE, Merck, Novartis.
Robert Raben, Raben Group: Amgen, GE.
Of course, this is how politics works. Lobbyists for various corporations and causes get involved wherever they can for candidates of both parties. But when you see all these big pharma (and insurance!) representatives coming with cash for a crucial vote, you know which side they’re on.

Comments are closed.